Demographic, clinical, biochemical, and immunological data for the 12 patients at presentation
| Patient No | M/F | Ethnic origin | Age (y) | Acute onset | AST (<50 IU/l) | Biliubin (<20 μmol/l) | ALP (<130 IU/l) | IgG (<18 g/l) | ANA | SMA | LKM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AST, aspartate aminotransferase; ALP, alkaline phosphatase—upper reference limits in parentheses; ANA, antinuclear antibodies; SMA, smooth muscle autoantibodies; LKM, type 1 antiliver-kidney microsomal antibodies. | |||||||||||
| *Presented with thyroid microsomal and thyroglobulin autoantibodies, became seropositive for ANA at 1:40 three months after starting immunosuppressive therapy. | |||||||||||
| 1 | F | African | 39 | Yes | 1803 | 22 | 232 | 25.3 | 1:10 | 1:160 | Neg |
| 2 | M | African | 16 | Yes | 2181 | 320 | 360 | 60.0 | 1:640 | Neg | Neg |
| 3 | F | African | 13 | No | 601 | 59 | 618 | 42.3 | 1:40 | 1:640 | Neg |
| 4 | F | Arabic | 13 | Yes | 1576 | 400 | 657 | 37.7 | Neg* | Neg* | Neg* |
| 5 | F | African | 28 | No | 579 | 43 | 262 | 29.2 | 1:1280 | 1:1280 | Neg |
| 6 | F | Asian | 33 | No | 191 | 227 | 466 | 22.7 | 1:20 | 1:80 | Neg |
| 7 | F | African | 32 | No | 980 | 90 | 647 | 70.7 | Neg | 1:160 | Neg |
| 8 | F | African | 12 | Yes | 850 | 280 | 850 | 36.0 | Neg | Neg | 1:640 |
| 9 | F | Asian | 19 | Yes | 847 | 469 | 186 | 46.8 | 1:40 | 1:320 | Neg |
| 10 | F | Asian | 51 | Yes | 1259 | 246 | 318 | 41.3 | 1:40 | 1:40 | Neg |
| 11 | M | Asian | 47 | No | 108 | 26 | 315 | 23.2 | Neg | 1:80 | Neg |
| 12 | F | Asian | 58 | No | 140 | 45 | 203 | 33.3 | Neg | 1:40 | Neg |